iBet uBet web content aggregator. Adding the entire web to your favor.
iBet uBet web content aggregator. Adding the entire web to your favor.



Link to original content: http://pubmed.ncbi.nlm.nih.gov/34440540/
Current Status of Next-Generation Sequencing-Based Cancer Genome Profiling Tests in Japan and Prospects for Liquid Biopsy - PubMed Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Aug 6;11(8):796.
doi: 10.3390/life11080796.

Current Status of Next-Generation Sequencing-Based Cancer Genome Profiling Tests in Japan and Prospects for Liquid Biopsy

Yumi Yoshii  1 , Shunsuke Okazaki  1 , Masayuki Takeda  1
Affiliations

Current Status of Next-Generation Sequencing-Based Cancer Genome Profiling Tests in Japan and Prospects for Liquid Biopsy

Yumi Yoshii et al. Life (Basel). .

Abstract

Next-generation sequencing-based comprehensive genome profiling (CGP) testing, OncoGuide NCC Oncopanel System, and FoundationOne CDx Cancer Genomic Profile have been covered by the Japanese national health insurance system since June 2019. Because CGP was initially developed to enroll patients into an early-phase clinical trial for solid tumors, its approved indications have been limited to patients who have completed the standard chemotherapy treatment. Approximately 14,000 cases have been registered with the Center for Cancer Genomics and Advanced Therapeutics as of March 2021. Measuring the drug access rate is not enough due to patients' deteriorating condition during CGP analysis and due to the limited number of ongoing clinical trials available, although tumor-agnostic therapies, such as the use of pembrolizumab in high microsatellite-instable solid tumors and in conditions with a high tumor mutational burden (≥10 mut/Mb) as well as the use of entrectinib and larotrectinib in NTRK fusion-positive tumors have been approved in Japan. Moreover, since this analysis is performed using DNA derived from tumor tissue, it is difficult to perform CGP in cases in which an insufficient amount of tissue exists. Thus, noninvasive blood-based assays have been developed, and CGP panels using circulating tumor DNA from blood were approved in March 2021. However, cost, timing, and the number of tests allowed by the health system have not yet been determined. Therefore, in this review, we outline the current status and issues of CGP testing using tumor tissues as well as the expectations and limitations of liquid biopsy for use in Japanese clinical practice.

Keywords: clinical sequencing; liquid biopsy; next-generation sequencing; precision medicine; solid cancer.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Sunami K., Ichikawa H., Kubo T., Kato M., Fujiwara Y., Shimomura A., Koyama T., Kakishima H., Kitami M., Matsushita H., et al. Feasibility and utility of a panel testing for 114 cancer-associated genes in a clinical setting: A hospital-based study. Cancer Sci. 2019;110:1480–1490. doi: 10.1111/cas.13969. - DOI - PMC - PubMed
    1. Kou T., Kanai M., Matsumoto S., Okuno Y., Muto M. The possibility of clinical sequencing in the management of cancer. Jpn. J. Clin. Oncol. 2016;46:399–406. doi: 10.1093/jjco/hyw018. - DOI - PubMed
    1. Takeda M., Sakai K., Terashima M., Kaneda H., Hayashi H., Tanaka K., Okamoto K., Takahama T., Yoshida T., Iwasa T., et al. Clinical application of amplicon-based next-generation sequencing to therapeutic decision making in lung cancer. Ann. Oncol. 2015;26:2477–2482. doi: 10.1093/annonc/mdv475. - DOI - PubMed
    1. Takeda M., Takahama T., Sakai K., Shimizu S., Watanabe S., Kawakami H., Tanaka K., Sato C., Hayashi H., Nonagase Y., et al. Clinical application of the FoundationOne CDx assay to therapeutic decision-making for patients with advanced solid tumors. Oncologist. 2021;26:e588–e596. doi: 10.1002/onco.13639. - DOI - PMC - PubMed
    1. Watanabe S., Takeda M., Otani T., Yoshida T., Sakai K., Olek E., Rothenberg S.M., Kherani J., French P.P., Nishio K., et al. Complete response to selective RET inhibition with selpercatinib (LOXO-292) in a patient with RET fusion-positive breast cancer. JCO Precis. Oncol. 2021;5:103–106. doi: 10.1200/PO.20.00282. - DOI - PMC - PubMed

LinkOut - more resources